You are here

Lightning strikes four times for Palmer

Andre Palmer, a global leader in blood substitute research and engineering biomaterials for use in transfusion medicine and tissue engineering, has received $8.4 million in R01 funding from the NIH in under a year.Andre Palmer, a global leader in blood substitute research and engineering biomaterials for use in transfusion medicine and tissue engineering, has received $8.4 million in R01 funding from the NIH in under a year.CBE Professor and Chairman Andre Palmer was awarded a fourth four-year R01 from the National Institutes of Health. The new R01, which totals $2.8M, focuses on enginering PEGylated earthworm hemoglobin as a safe and efficacious red blood cell substitute for use in transfusion medicine.

Palmer's team includes co-PIs from the University of California San Diego and The Ohio State University Wexner Medical Center.

The latest R01 - the fourth received in under a year - brings Palmer's NIH R01 total to $8.4M. 

Palmer is also expecting a Department of Defense grant which recently received approval.

 

 

Tags: Top News